Qrono reformulates FDA approved drugs and creates long-acting injectable (LAI) medications with improved clinical and economic benefits. Our product pipeline focuses on therapeutic areas where LAIs offer high therapeutic and economic value, such as high non-adherence, or solving specific drug delivery challenges.
Using our computational drug delivery software, we can design LAIs much faster than the legacy practice and with reduced regulatory and technical risk. We further reduce risk since we are starting with FDA approved drugs that have known safety, known efficacy, and known market success. We use the accelerated FDA 505(b)(2) regulatory process that enables regulatory approvals 3X as fast at 1/3 the cost of new drug applications.
Qrono is a pioneer in applying our proprietary computational drug delivery technology, called QronoMetrics™, to develop these long-acting drug formulations significantly faster than current practice. We can achieve the optimal design up to 95% faster than current best practice while significantly reducing regulatory and technical risk.
Qrono offers significant value to our customers and the medical community:
Improved adherence rates, better outcomes, and reduced side effects for patients;
Faster time-to-market (worth up to many $100 MM’s in patent protected revenue);
Reduced formulation development costs ($500K – $1MM);
Reduced active pharmaceutical ingredient (API) costs (up to 60% less API);
Reduced regulatory risk;
Reduced manufacturing scale-up risk; and
Significantly reduced risk of formulation performance problems or failure.